Cambridge Healthtech Institute’s 17th Annual

Engineering Bispecific and Multispecific Antibodies

Achieving Unprecedented Efficacy

May 14-15, 2026

Incredible progress has led to the proliferation of bispecific and multispecific antibodies that are engineered to combine multiple antigen-binding sites into a single molecule and enable the targeting of two or more antigens to allow new biological activities and greater therapeutic power. The latest efforts to increase complexity by creating trispecifics and beyond are leading to significant improvements in specificity and selectivity while introducing novel functionalities, but this also requires efforts at reducing toxicity and off-target effects. This field is poised for significant advances and is leading the way for novel breakthroughs in biologics.

Coverage will include, but is not limited to:

Launching novel conditionally active formats
Engineering antibody-cytokine fusions
Investigating novel mechanisms of action
Engineering trispecific immune-cell engagers for treating solid tumors
Integrating ML/AI in the selection and optimization of multispecific antibodies
Predicting developability of bispecific molecules with ML/AI tools
Designing checkpoint-inhibitor and bispecific-combination therapeutics
Developing CAR Ts and bispecifics to achieve better outcomes
Multispecifics for non-oncology applications
Reviewing emerging trispecific formats

The deadline for priority consideration is October 17, 2025.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: